Company Overview and News

9
FCSC / Fibrocell Science Inc. 8-K (Current Report)

13h sec.gov
Document UNITED STATES
FCSC

35
FCSC / Fibrocell Science Inc. 8-K (Current Report)

2018-06-12 sec.gov
Document UNITED STATES
FCSC

22
Intrexon (XON) Down 9.2% Since Earnings Report: Can It Rebound?

2018-06-11 zacks
It has been about a month since the last earnings report for Intrexon Corporation (XON - Free Report) . Shares have lost about 9.2% in that time frame.
GJV HSC XON NWS NWSA FCSC

19
Press Release - Fibrocell : Fibrocell

2018-06-07 ir.fibrocell
– Continued positive trends noted in wound healing and pharmacology signals, including type VII collagen expression and evidence of anchoring fibrils –
XON FCSC

5
FCSC / Fibrocell Science Inc. / Frigate Ventures LP - SC 13G (Passive Investment)

2018-06-01 sec.gov
SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
FCSC

6
FCSC / Fibrocell Science Inc. / Frigate Ventures LP - SC 13G (Passive Investment)

2018-06-01 sec.gov
SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
FCSC

8
FCSC / Fibrocell Science Inc. 8-K (Current Report)

2018-05-31 sec.gov
Document UNITED STATES
FCSC

15
Fibrocell Announces Closing of $6.0 Million Registered Direct Offering

2018-05-31 globenewswire
EXTON, Pa., May 31, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the closing of its previously announced registered direct offering of 2,038,224 shares of its common stock which was priced at-the-market at a purchase price of $2.85 per share, for gross proceeds of approximately $5.
XON FCSC

5
FCSC / Fibrocell Science Inc. / Sabby Management, LLC - SABBY 13G FCSC 5.31.18 (Passive Investment)

2018-05-31 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.______)* Fibrocell Science Inc (Name of Issuer) Common Stock (Title of Class of Securities) 315721407 (CUSIP Number) May 29, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the dis
FCSC

11
FCSC / Fibrocell Science Inc. / Sabby Management, LLC - SABBY 13G FCSC 5.31.18 (Passive Investment)

2018-05-31 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.______)* Fibrocell Science Inc (Name of Issuer) Common Stock (Title of Class of Securities) 315721407 (CUSIP Number) May 29, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the dis
FCSC

10
FCSC / Fibrocell Science Inc. 424B5 (Prospectus)

2018-05-31 sec.gov
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-209077
FCSC

15
Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market

2018-05-29 globenewswire
EXTON, Pa., May 29, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 2,038,224 shares of its common stock, at a purchase price per share of $2.
XON FCSC

6
FCSC / Fibrocell Science Inc. 8-K (Current Report)

2018-05-28 sec.gov
Document UNITED STATES
FCSC

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 315721209